Mark Mchale
Chief Operating Officer
Cancer
ASLAN
Singapore
Biography
Dr Mark McHale is Chief Operating Officer and Founder of ASLAN Pharmaceuticals. Previously, Mark was Head of Molecular Sciences at AstraZeneca Respiratory & Inflammation, and in this role supported small molecule and therapeutic antibody projects from target identification to phase 2a. Mark was a core member of the respiratory strategy research team for half a decade and personally led all new target identification in asthma. In 2006, Mark led a $136M investment in the AZ/Dynavax collaboration to produce inhaled TLR9 agonists for the treatment of asthma and led preclinical / phase 1 projects.
Research Interest
Cancer
